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HIGHLIGHTS:
 Schizophrenia patients present with impaired cognitive functions.
 Evidence suggests strong genetic etiology for cognitive deficits in schizophrenia.
 Neurotransmitter system genes showed effect on cognitive deficits in schizophrenia.
 Limited evidence suggests the dopaminergic system genes with inconsistent findings.
 Larger samples are required to examine genetic risk of cognition in schizophrenia.
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ABSTRACT (Word count = 170):
Schizophrenia is a complex and debilitating illness with strong genetic loading.  In line 
with its heterogeneous symptomatology, evidence suggests genetic etiologies for the phenotypes 
in schizophrenia.  A search across endophenotypes has pointed towards consistent findings in its 
neurocognitive deficits.  Extensive literature has demonstrated impaired cognition including 
executive function, attention, and memory in schizophrenia patients when compared to healthy 
subjects.  This review 1) provides an overview of recent studies and 2) develops an up-to-date 
conceptualization of genetic variations influencing neurocognitive functions in schizophrenia 
patients.  Several neurotransmitter system genes have been examined given knowledge of their 
role in brain functions and their reported genetic associations with schizophrenia and cognition.  
Several genetic variations have emerged as having preliminary effects on neurocognitive deficits 
in schizophrenia.  These include genes in the neurotrophic, serotonin, cell adhesion, and sodium 
channel systems.  Limited evidence also suggests the dopaminergic system genes, with the most 
studied catechol-o-methytransferase (COMT) gene showing inconsistent findings.  Further 
investigations with larger samples and replications are required to elucidate genetic risk for 
cognitive deficits in schizophrenia.
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INTRODUCTION
Schizophrenia is a chronic and severe neuropsychiatric disorder with a lifetime 
prevalence of 0.4-1% in the general population (1, 2).  The core features of this disorder are 
characterized by three symptom domains including positive symptoms, negative symptoms, and 
cognitive deficits (1).  The identification of neurocognitive deficits in schizophrenia patients is 
important because cognitive impairment is associated with poor functional outcome (3).  Up to 
98% of schizophrenia patients have a degree of neurocognitive impairment (4, 5).  Although 
antipsychotic medications reduce positive symptoms significantly, they have limited efficacy for 
remediating neurocognitive deficits and negative symptoms of schizophrenia (6, 7).
Cognitive dysfunction has repeatedly been identified as one of the hallmark features of 
schizophrenia starting as early as 1950 by Bleuler (8) and recently in the past decade (3, 4, 9, 
10).  A systematic review reported global cognitive impairment and specifically worse verbal 
memory, executive function, and general IQ, in first-episode psychotic patients when compared 
to healthy controls (11).  Recent meta-analyses also detected significant deficits in working 
memory, attention/vigilance, verbal/visual learning and memory, executive functions (reasoning 
and problem solving), processing speed, social cognition, and psychomotor control (7, 12).
Evidence has shown that schizophrenia and cognitive impairment have heritability 
ranging between 70-90% and 24-55% respectively (13, 14).  Schizophrenia is a complex and 
heterogeneous neuropsychiatric disorder with a polygenic architecture (15) and even following 
recent genome-wide association studies (GWAS) (16, 17), multiple small gene effects with only 
several replicable findings have been found to contribute to risk.  Therefore, the identification of 
endophenotypes, with an attempt to ascertain a more homogeneous phenotype for genetic 
studies, is important for elucidating the etiology of schizophrenia.  The search for 
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endophenotypes is guided by their strong association with the illness, high heritability, and 
observable similar deficits in unaffected relatives (18).  Cognitive deficits are heritable and are 
core features of schizophrenia, thus they may be valuable endophenotypes for schizophrenia.  
Twin studies (19-21) and two recent molecular genetic studies (22, 23) have reported significant 
genetic overlap between neurocognition and schizophrenia.  Additionally, neuropsychological 
studies have observed that unaffected relatives of schizophrenia patients performed significantly 
worse in estimated intelligence, immediate and delayed logical memory, immediate visual 
reproduction, and sustained attention, therefore implicating genetic loading within families (24-
26).  Although research on the genetics of neurocognitive domains in schizophrenia has grown 
rapidly over the last decade in parallel with attempts to determine the genetic etiology of 
schizophrenia, the last review to have covered some genetic studies of cognitive endophenotypes 
in schizophrenia was published in 2008 (27).  Therefore, we now provide an up-to-date review of 
this important topic.
Methods:
We reviewed all molecular genetic studies of cognition in schizophrenia that were 
published in PubMed and/or MEDLINE until January 1, 2015.  Specific search terms used 
included: genetics, molecular genetics, schizophrenia, cognition, neurocognition, cognitive or 
neurocognitive or neuropsychological deficits or impairments or endophenotypes or traits.  
Eighty-twoSeventy-three  original studies were included in this review article.  A summary can 
be found on Table 1 (Table S1 in Supplement 1 for full details).
Results:
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Many genes have been reported to be associated with cognitive impairment in 
schizophrenia as shown in Table S1 in Supplement 1.  The next sections of this review will 
provide a comprehensive summary of these genetic findings organized according to important 
bio-molecular systems (Figure 1).
Dopaminergic System Genes:
The dopaminergic system genes that have been investigated in neurocognitive deficits of 
schizophrenia include catechol-O-methyltransferase (COMT) (10, 28-47), dopamine transporter 
(DAT) (10, 28, 41, 47, 48), dopamine D1 receptor (DRD1) (10), dopamine D2 receptor (DRD2) 
(10, 43, 45), dopamine D3 receptor (DRD3) (10, 46, 48), dopamine D4 receptor (DRD4) (30), 
dopamine D5 receptor (DRD5) (49), dopamine beta-hydroxylase (DBH) (12, 46), vesicular 
monoamine transporter 2 (SLC18A2) (10, 46), ankyrin repeat and kinase domain containing 1 
(ANKK1) (10), and protein phosphatase 1, regulatory (inhibitor) subunit 1B (PPP1R1B) (10).
The most extensively examined candidate gene in neurocognition of schizophrenia is 
COMT.  A reduction in dopaminergic neurotransmission in specific brain regions such as the 
anterior cingulated and the dorso-lateral prefrontal cortex has been postulated to alter cognition, 
specifically executive function and working memory, in schizophrenia (50).  A functional 
polymorphism within COMT, Val158Met, accounts for a four-fold variation in its enzymatic 
activity and dopamine catabolism in the prefrontal cortex, with Met as the low functioning allele 
(34).  Twenty three studies were found as defined by our search criteria (31).  Barnett et al. (31) 
performed a meta-analysis including 12 studies of the impact of COMT Val158Met on executive 
function and detected significant association between Val/Val and worse cognitive performance 
than Met/Met only in healthy controls but not in schizophrenia patients.  A recent study (43) 
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similarly reported no association between this locus and theory of mind dysfunction in 
schizophrenia but detected worse performance in Met-carrier females in the combined 
schizophrenia and control sample.  However, a 94-multi-gene family study examining COMT, 
found associations with verbal learning, ‘false’ memory, and prepulse inhibition in schizophrenia 
patients (44).  Twamley et al. (51) also reported better learning, memory, and abstraction with 
the Met allele than Val, and when Green et al. (52) investigated cognitive function in 
schizophrenia patients with childhood trauma history, they detected significant links of the Val 
homozygotes with worse cognitive performance in the absence of childhood adversity, and better 
executive function with positive abuse history, suggesting a gene-environment interaction.  
Overall, given the pleiotropic effects of most genes, it appears unlikely that changes in cognition 
in relation to COMT are specific to schizophrenia.
Other dopamine-related genes, DAT, DRD1, DRD2, DRD3, DRD4, DRD5, DBH, 
SLC18A2, ANKK1, and PPP1R1B, have also been investigated in cognitive deficits of 
schizophrenia.  These genes were examined because of their prior association with schizophrenia, 
antipsychotic actions, and/or their involvement in dopamine neurotransmission.  Four studies 
involved DAT, one with rs6350 and three with the functional 3’ VNTR, but none reported 
association with cognitive measures in schizophrenia (28, 41, 47, 48).  Three studies investigated 
DRD2 markers in executive functioning (45) and theory of mind impairment (43) in 
schizophrenia (10) and all were negative.  Two significant and one negative studies of DRD3 
have been published.  Firstly, Szekeres et al. (48) reported a significant association between the 
DRD3 Ser9Gly low functioning (53) Ser/Ser genotype and fewer categories completed and more 
perseverative errors on the Wisconsin Card Sort Test (WCST) than Ser/Gly.  Secondly, a 94-
multi-gene study reported a significant association between DRD3 and emotional recognition 
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(44).  However, Bombin et al. (45) only detected significant associations of DRD3 in the 
combined first-episode psychosis and healthy adolescents suggesting a lack of power.  One 
DRD5 study (49) reported a significant association between the presence of two copies of the 7 
(148-bp) allele in the (CT/GT/GA)n microsatellite and lower word generation (visual voluntary 
attention) than one copy of the 7 allele in schizophrenia (P=0.018) and their relatives.  Kukshal 
et al. (46) reported no association between COMT, DRD3, DBH, and SLC18A2 with performance 
in the Trail Making Test.  For the DBH 19-bp deletion, Hui et al. (12) detected significantly 
poorer immediate memory with the carriers in schizophrenia patients but not in controls.  Several 
markers across DAT, DRD1, DRD3, and SLC18A2 were also found to be significantly associated 
with poorer cognitive functions in schizophrenia patients in a multi-gene study (10).
Thus, dopamine-related genes may be implicated to a limited extent in the neurocognitive 
deficits in schizophrenia patients, especially in memory, attention and executive function.  
However, except for COMT, few studies have examined other dopamine-related genes and recent 
GWAS of cognitive performance in schizophrenia (22, 23, 54, 55) failed to implicate any 
dopamine-related genes, suggesting the existence of additional possible mechanisms and 
interactions in the genetic etiology of neurocognitive deficits in schizophrenia and the need for 
more systematic studies.
Neurodevelopmental and Neuroplasticity Genes:
Genes related to neurodevelopment and neuroplasticity are obvious candidates for 
cognitive deficits in schizophrenia.
The dystrobrevin binding proteint 1 (DTNBP1) gene encodes dysbindin, a key subunit of 
the biogenesis of lysosome-related organelles complex-1, which regulates protein trafficking and 
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cell-surface expression of neurotransmitter receptors (56).  It has been shown to modulate 
prefrontal cortical activity via glutamatergic neurotransmission (57, 58).  Significant reduction of 
DTNBP1 in glutamatergic neuronal terminal fields in the hippocampus has been reported and 
Talbot et al. (57) postulated that glutamatergic dysconnectivity may contribute to cognitive 
impairment in schizophrenia.  Three Four studies examined the effect of this gene in cognitive 
deficits of schizophrenia.  Burdick et al. (59) first demonstrated an association between a 
schizophrenia risk haplotype of DTNBP1 (rs909706-rs1018381-rs2619522-rs760761-rs2619528-
rs1011313), CTCTAC, and greater decline in IQ in 183 schizophrenia/schizoaffective disorder 
patients.  Baek et al. (60) later reported a significant association between DTNBP1 rs760761 and 
rs1018381 and the attention/vigilance domain when comparing schizophrenia patients to 
controls.  Another study (61) reported that the DTNBP1 rs2619539-rs3213207-rs2619538 C-A-T 
haplotype was associated with impaired spatial working memory performance.  However, one 
study (62) did not report any association between single tagging sequence variants and their 
relevant haplotypes across DTNBP1 and neurocognitive endophenotypes in schizophrenia after 
separating individuals into cognitive deficit and cognitive sparing groups.
The disrupted in schizophrenia 1 (DISC1) gene is considered to be a central hub of 
cellular development and regulation given its importance in neurogenesis and neuroplasticity 
(63).  It has been previously shown to be associated with schizophrenia, initially from a large 
multiplex family although not specific to schizophrenia (64) and a recent European meta-analysis 
(65).  Furthermore, the down-stream cascade of DISC1 and its interaction with 
phosphodiesterase-4B have been implicated in learning, memory, and mood (66).  Thus, DISC1 
has become a candidate for the genetic study of neurocognitive dysfunctions in schizophrenia 
(67).  Only threeFive studies have been reported.  The first (68) reported an association between 
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the DISC1/translin-associated factor X (TRAX) haplotype and impairments in short- and long-
term memory and reduced gray matter density in the prefrontal cortex.  The second (69) reported 
an association between the DISC1-HEP3 (rs751229-rs3738401) haplotype and poorer 
performance on short-term visual memory and attention.  The third demonstrated a significant 
finding between DISC1 rs821616 Ser/Ser genotype and reduced performance on WMS Logical 
Memory II subsection in schizophrenia patients in addition to a lower WCST category scores in 
the entire sample (schizophrenia, unaffected siblings, parents, and healthy controls) (70).  
Burdick et al. (71) observed positive association between DISC1 rs2255340 genotype and rapid 
visual search and verbal working memory.  The last is a recently published multi-gene study (28) 
who reported a trend association between DISC1 rs12133766 and deficient verbal fluency in 
schizophrenia males (P=0.049).
Neurotrophic factors have been postulated to affect cognition given their roles in 
neuroplasticity and their interactive and modulatory effects on various neurotransmitter systems.  
The brain-derived neurotrophic factor (BDNF) gene has been examined due to its role in cell 
differentiation, survival, long-term potentiation, synaptic plasticity, learning, and memory (72-
75).  Its functional polymorphism, rs6265 (Val66Met), has been extensively investigated with 
prior significant associations in memory impairment (76) and schizophrenia (77).  Three Eight 
studies in addition to a multi-gene study and a meta-analysis including twoseven studies from 
our search were detected.  The first studyEgan et al. (78) detected a significant association 
between individuals with one or two Met allele(s) regardless of their disease status 
(schizophrenia patients, their healthy siblings, and healthy controls) and lower abilities to 
perform tasks of learning and memory.  Another study (79) reported that schizophrenia patients 
with the high-functioning Val/Val genotype of BDNF Val66Met had superior scores for both 
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voluntary and involuntary attention tasks, in contrast to the serotonin 2A receptor gene (HTR2A 
T102C)T-Met combination, linked to inferior performance for voluntary attention but superior 
performance for involuntary attention.  Ho et al. (80) reported observed a significant association 
between the BDNF Met allele with poorer verbal memory performance in both schizophrenia 
patients and healthy volunteers, and visuospatial impairment in schizophrenia only.  Val carriers 
were found to be associated with better visuospatial and constructional performance in both 
schizophrenia and healthy subjects whereas only schizophrenic Met carriers had significantly 
greater attention impairment (81).  In another study, schizophrenic Met carriers showed higher 
percentage of WCST perseverative errors especially in males (82).  Although Rybakowski et al. 
(83), Ho et al. (84), and Chung et al. (85) reported no association between BDNF Val66Met and 
cognitive performance on WCST but, Rybakowski et al. (80) demonstrated that Val/Val was 
significantly associated with higher correct responses on the N-back test.  A recent meta-
analysis, which included 12 studies including Egan et al. (78), Ho et al. (80),  Rybakowski et al. 
(83), Ho et al. (84), Chung et al. (85), Lu et al. (82), and Zhang et al. (81) compared 
neurocognitive domain scores between Met carriers and Val homozygotes in 1890 schizophrenic 
patients and did not report any significant difference (86) and a recent multi-gene study also did 
not support a role of BDNF in schizophrenia patients with cognitive deficits (Nicodemus et al., 
2013).
Although threewo of the three four studies above showed modest significant association 
between DTNBP1 variants and poor cognitive performance in schizophrenia patients, and three 
five studies suggested some associations of DISC1 genetic variants in neurocognitive deficits in 
schizophrenia, the recent GWAS (23) support neither of these genes as being strongly related to 
schizophrenia.  Furthermore, a recent meta-analysis did not support the involvement of BDNF 
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Val66Met in psychotic patients with neurocognitive deficits.  Thus, the overall status of these 
genes in neurocognitive function in schizophrenia remains unresolved. 
Glutamatergic System Genes:
The glutamatergic neurotransmitter system has received much attention given its 
neuronal excitatory properties in network functions throughout the brain, especially in the 
cerebral cortex, its influence in psychotic and cognitive symptoms, as well as being a source of 
potential drug targets (87, 88).  In animal studies, the mGluR3 knockout mouse showed 
hyperactivity and impaired working memory (89, 90), and these cognitive deficits are consistent 
with those of schizophrenia patients (7, 11).  Reduction in glutamate levels has also been found 
in schizophrenia patients with impaired cognitive control functioning but not in healthy controls 
(87).
Effects of glutamatergic modulatory drugs such as mGluR2/3 agonists (i.e. metabotropic 
glutamate receptor group II agonists), have been investigated in animal models of schizophrenia 
(91, 92).  Other drugs that regulate activation or inhibition of the N-methyl-D-aspartate (NMDA) 
receptor including the glycine transporter-1 inhibitors (93) and NMDA receptor antagonist (94) 
have also been investigated for their potential role in the treatment of cognitive impairment in 
schizophrenia.  These medications have had mixed results in early clinical trials in schizophrenia 
but more recently, a mGluR2/3 agonist has shown promising results in the treatment of early 
psychosis (95), possibly with relatively good efficacy for cognition, in particular, working 
memory (96).
Of the glutamatergic system genes, only three have been studied: the glutamate receptor, 
ionotropic, N-methyl-D-aspartate, subunit 2B (GRIN2B) (28, 97), GRIN2A (97), and glutamate 
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receptor, metabotropic 3 (GRM3) (97).  Jablensky et al. (97) reported a significant association 
between the GRIN2B rs220599 T allele with poorer immediate and delayed recall on the Rey 
Auditory Verbal Learning Test; however, Nicodemus et al. (28) did not detect any positive 
findings with this gene in cognitive deficits of schizophrenia.  Jablensky et al. (97) also observed 
enhanced cognitive performance with the GRM3 rs2189814 C allele but not with GRIN2A.
Very few studies of glutamate system genes have examined neurocognitive impairments 
in schizophrenia, although new medications targeting the glutamatergic system have shown 
possibly promising results in the treatment of cognitive deficits in schizophrenia and in reducing 
psychosis.  The use of genetic tools to subdivide groups of patients in trials of new glutamatergic 
drugs may help to identify patients, whose cognition will show greater improvement, thus 
pointing to more personalized treatment options.
Serotonergic System Genes:
The serotonergic system interacts with many neurotransmitter systems and serotonin 
plays a important role in the regulation of morphogenesis in CNS development, neuronal 
proliferation, migration, differentiation, and cognition (98-100).  In term of gene expression, the 
frontal cortex and anterior cingulate cortex have approximately 10-fold higher mRNA expression 
of the serotonin 2A receptor (HTR2A) than hippocampus or caudate and putamen according to 
the Genetic Tissue Expression database (GTEx: http://www.gtexportal.org).
Five studies have examined the HTR2A T102C polymorphism (28, 79, 101-103) with 
three significant associations.  As mentioned above, Alfimova et al. (104) reported a significant 
association between the T allele and more time for performing the test in addition to the T-
(BDNF Val66Met)Met combination and lower scores for voluntary attention and higher scores 
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for involuntary attention.  Uçok et al. (103) reported significant associations between the high 
expression (105) T allele with a lower hit rate in Continuous Performance Task (CPT) and the 
T/C genotype with more commission errors on CPT and fewer correct responses on WCST.  
Alfimova et al. (101) reported a significant association between the T/T homozygotes and lower 
verbal fluency in male schizophrenia patients only and not the entire sample, including controls.  
Although Chen et al. (102) did not detect a significant association between the HTR2A T102C 
polymorphism and cognitive deficits in schizophrenia patients.  The authors observed a trend 
between T/C genotype and better verbal fluency and less motor co-ordination soft neurological 
signs.  Nicodemus et al. (28) however did not demonstrate any role of this genetic variation in 
cognitive deficits in schizophrenia.
Besides HTR2A, one study of the serotonin 1A receptor (HTR1A) (106) and three studies 
of the serotonin transporter (5HTT, also known as SLC6A4) (107) have been conducted.  Bosia et 
al. (106) reported schizophrenia patients with the low-expression (108) CC genotype of HTR1A -
1019C/G polymorphism performed better on Theory of Mind tasks.  Bosia et al. (107) reported a 
significant association between the HTTLPR polymorphism and executive function and sustained 
attention, specifically the high activity long allele with better executive performance and with 
poorer attention, but two additional studies were negative (45, 47).
Genome-Wide Association Studies (GWAS):
To date, five GWAS have been published recently (see Table S1 in Supplement 1 for full 
details).  The first GWAS was published in 2012 and written in Chinese (109).  Xiang et al. 
(109) identified five risk genes, which were associated with memory deficits.  The second 
GWAS examining genetic influence of neurocognitive traits in schizophrenia found the strongest 
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genetic enrichments for performance in a colour-interference Stroop test and sets associated with 
the rate of learning (23).  The third GWAS (22) reported significant genetic overlap between 
general cognitive ability and risk for schizophrenia, implicating similar pathophysiological 
processes between the two.  Although schizophrenia patients had lower general cognitive ability 
than healthy controls, the authors did not detect genome-wide significance.  In the meta-analysis 
(22), they observed significant association between MAD1 mitotic arrest deficient-like 1 
(MAD1L1) and cyclin M2 (CNNM2) and lower general cognitive ability.  Additionally, the 
LSM1 homologue, U6 small nuclear RNA associated (LSM1) and the neurogranin (protein 
kinase C substrate, RC3) (NRGN) schizophrenia risk alleles were associated with higher 
cognitive ability in schizophrenia patients (22).  Through the recent PGC schizophrenia GWAS, 
Hargreaves et al. (54) detected an increased polygenic risk score for the cell adhesion molecule 
pathway with poorer performance on memory and attentional tasks.  The strongest signal was 
detected within the human leukocyte antigen system, HLA-DQA1 rs9272105 marker, which was 
associated with attentional control only.  The latest GWAS (55) showed genome-wide significant 
associations between cognitive ability in schizophrenia and polymorphisms in the sodium 
channel, voltage-gated, type II, alpha subunit (SCN2A) gene.
Genetics of Normal Cognition, Alzheimer’s Disease, and Other Cognitive Disorders:
General intelligence may in fact play a role in cognitive deficits of schizophrenia patients.  
Therefore, we included a brief summary of the genetics of general intelligence in healthy 
individuals and patients with cognitive disorders in order to determine whether there are distinct 
genetic risks that differentiate between healthy individuals, patients with cognitive disorders, and 
schizophrenia patients with cognitive deficits.
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A GWAS of general intelligence has not yielded genome-wide significance in 3,511 
healthy adults (110); however, using a gene-based approach, Davies et al. (110) detected a 
genome-wide significant association with the forming-binding protein 1-like (FNBP1L) gene but 
it was not replicated in an independent sample from the same study.  The apolipoprotein E 
(APOE) gene was found to be associated with cognition in older individuals, suggesting a 
genetic overlap with Alzheimer’s disease (111).  A recent review article on GWAS in 
Alzheimer’s disease identified several major pathways, including amyloid, immune system, 
inflammation, lipid transport and metabolism, synaptic functioning, and endocytosis (112).  
Similarly in a recent review of the genetics of recessive cognitive disorders, significant 
associations have been found in genes that are involved in synaptic function, basic cellular 
processes including DNA transcription, translation, and degradation, mRNA splicing, energy 
metabolism, and fatty-acid synthesis and turnover (113, 114).
There are genetic overlaps between general intelligence in healthy individuals, cognitive 
disorders, and cognitive deficits in schizophrenia (Table 2).  Interestingly, energy metabolism 
appears to be a common genetic pathway that affects cognition regardless of disease status.  
Nonetheless, many genes have been detected in specific disorders but replication studies are 
required to further expand on these reports and to differentiate disease-specific genetic markers. 
Treatment Implications:
Pharmacotherapy of schizophrenia has only shed light in the treatment of positive, but not 
cognitive or negative symptoms.  No known treatment has provided significant improvement in 
these latter symptoms to date.  Since cognitive and negative symptoms are associated with poor 
functional outcome, the development of new pharmacological strategies is crucial for reducing 
Zai et al. 18
disease-related disability.  Recent studies of cognitive enhancers and immunomodulatory drugs 
have reported promising effects on cognition in schizophrenia (115, 116); however, replications 
are warranted to provide support for clinical application.  Thus, the search for genetic 
vulnerability in cognition and eventual discovery of a biomarker will enable researchers to 
identify new drug targets, which will hopefully lead to the improvement of cognitive deficits in 
schizophrenia patients.
Discussion:
This is the first comprehensive attempt to review all molecular genetic studies of 
cognitive impairments in schizophrenia to date.  Neurocognitive deficits are one of the key 
symptom dimensions of schizophrenia.  The study of cognition in schizophrenia is a strong and 
important unmet need for new drug targets since cognitive deficits are often the most difficult to 
treat.
Although 73 82 publications were qualified according to our search criteria, a 
considerable expansion of current work will be required to further identify risk loci for cognitive 
dysfunction in schizophrenia.  Multiple genetic variants have been examined in different 
cognitive domains in schizophrenia but there have been few replication studies to date.  The most 
examined candidate genes include COMT, DISC1, HTR2A, and BDNF, which all provided 
inconsistent findings, often associated with different aspects of cognitive dysfunction in 
schizophrenia.
Evidence has suggested overlapping genetic etiology between neurocognition and 
schizophrenia (21).  Although the number of molecular genetic studies is growing, these studies 
use traditional clinical and convenient neuropsychological test measures, which are often 
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insensitive, non-specific, and neurally ill-defined.  The hope is for a more homogeneous 
phenotype; however, current studies often use the label of cognitive impairment loosely in 
schizophrenia.  Many of these studies focused on genes that were previously implicated in 
schizophrenia and very few of them have investigated interactions between genetic variations 
across different genes.  Calcium and sodium channels have emerged in recent schizophrenia 
genetic association studies as well as the most recent GWAS examining cognitive impairment in 
schizophrenia.  These will hopefully lead researchers to search for an underlying common 
mechanism that may partly explain the etiology of schizophrenia and its related cognitive 
deficits.  Advances in bioinformatics are allowing researchers to analyze large datasets despite 
the relatively low prevalence of schizophrenia and multiple common loci explaining only small 
fractions of the genetic variance.  Linking functional implication to identified genetic markers 
(e.g., expression via GTEx) and testing these functional hypotheses may prove to advance our 
understanding of the etiology of neurocognitive dysfunction in schizophrenia.
The complexities of both schizophrenia and cognition provide additional challenges 
including the potential role of illness epiphenomena and illness-specific mechanisms of cognitive 
impairment.  Furthermore, one of the two twin studies that have examined the genetic influences 
in schizophrenia and cognition detected limited genetic overlap between the two (117).  
Suggestive of the lack of overlap can be observed in two schizophrenia risk alleles counter-
intuitively being associated with better cognitive performance (22).  Common genetic markers 
affecting cognitive performance in schizophrenia may not have been detected at present given 
the complex interactions of genetic, environmental, and random influences that affect individuals 
across their developmental stages and lifespan.  Investigating interactions between other 
endophenotypes of schizophrenia that may be related to cognitive functions, such as 
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neuroimaging findings, are potentially crucial for linking genetics to brain structure and function.  
Larger sample sizes with definition of homogeneous subgroups may aid in the identification of 
specific and shared genetic markers that influence schizophrenia and cognition.  Moreover, there 
are numerous different facets of neurocognition and many different methods for testing these 
cognitive domains; thus, development of a broad battery of systematic and well-standardized 
cognitive tasks that are reliable, easy to interpret, and comparable based on modern cognitive 
neuroscience approaches will be required in order to derive more definitive conclusions.  
Significant associations with performance on a single test of a particular function such as 
working memory or attention will ideally be supported by more than one test measure.  The 
behavioural specificity of such effects will also need to be carefully assessed.  One major, though 
controversial, hypothesis relating to intellectual deficits in schizophrenia is that it may be driven 
by the general factor, g, from conventional IQ tests (118, 119).  The relationship of specific, or 
general, aspects of cognition to identified neural system dysfunction is also required so that 
neurocognitive phenotypes and endophenotypes can be accurately delineated.
Further research is warranted to target known hypotheses and mechanisms of cognitive 
deficits in schizophrenia, which may in turn contribute to the development of preventative 
measures and new drug targets.  Cognitive deficits in schizophrenia are associated with poor 
functional outcome and therefore, the identification of biomarkers to predict different outcomes 
may influence treatment options including the intensity, duration, choice of medication, and type 
of therapy such as brain stimulation.  Genetic markers related to electrophysiology and/or 
neuroplasticity such as BDNF may attract interest and attention in treatment utilizing brain 
stimulation techniques.   New advances in differentiating cognitive deficits, impairment in social 
cognition, and negative symptoms of schizophrenia, including motivational and emotional 
Zai et al. 21
measures, may further delineate different subgroups within the current schizophrenia population.  
Genetic biomarkers may aid in the identification of these subgroups, which may in turn translate 
into clinical utility via personalized medicine.
Word Count: 4000 4296 including track changes (excluding title page, abstract, 
acknowledgements, references, tables, and figures).
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Figure 1. Candidate gene studies according to their biomolecular systems.  Dopaminergic system genes have been examined the most in genetic 
studies of cognition in schizophrenia given the important role of dopamine in the etiology of schizophrenia and cognition.  Neurodevelopmental 
genes are amongst the second most commonly studied candidate, followed by serotonergic and glutamatergic system genes.  Although the glutamate 
hypothesis in schizophrenia has sparked new insight into the mechanism of schizophrenia, only 4% of studies have examined genes related to 
glutamatergic system.
Table 1. Molecular genetic studies of cognitive deficits in schizophrenia (for full details, please refer to Table S1 in Supplement 1).*
Candidate Gene 
Studies SignificantSystem Gene N
Positive Negative Multi-gene GWAS
Cognitive Domains Reference
Dopamine COMT 23 12 11 2 - Executive function, theory of mind, reaction time, processing speed, attention, IQ, spatial working memory, attentional flexibility and planning (1-25)
DAT/SLC6A3 4 0 4 1 - - Speed of information processing, attention/vigilance, verbal learning and memory, working memory, reasoning and problem solving, set shifting, and verbal comprehension
(1, 7, 21, 
23, 26)
DRD1 - - - 1 - - Speed of information processing, attention/vigilance, verbal learning and memory, working memory, reasoning and problem solving, set shifting, and verbal comprehension (23)
DRD2 2 0 2 1 - - (2, 22, 23)
DRD3 3 1 2 1 -
Perseveration
- Speed of information processing, attention/vigilance, verbal learning and memory, working 
memory, reasoning and problem solving, set shifting, and verbal comprehension
(20, 22, 23, 
26)
DRD4 1 1 0 - - Working memory, verbal fluency (5)
DRD5 1 1 0 - - Visual voluntary attention (27)
DBH 2 1 1 - - Immediate memory (20, 28)
SLC18A2 1 0 1 - - - Speed of information processing, attention/vigilance, verbal learning and memory, working memory, reasoning and problem solving, set shifting, and verbal comprehension (20)
ANKK1 - - - 1 - - (23)
PPP1R1B - - - 1 - - (23)
Neuro DISC1 5 5 0 2 - Verbal fluency, verbal working memory, short- and long-term memory, short-term visual memory, visual search, attention
(1, 17, 23, 
29-32)
DTNBP1 4 3 1 1 - Attention/vigilance domain, spatial working memory, IQ (23, 33-36)
BDNF 8 5





Voluntary and involuntary attention, verbal memory, visuospatial skills, working memory
- Speed of information processing, attention/vigilance, verbal learning and memory, working 
memory, reasoning and problem solving, set shifting, and verbal comprehension
(1, 23, 37-
45)
NRG1 2 2 0 2 - Processing speed, visuomotor speed, attention, long-term episodic memory, short-term memory (17, 23, 46, 47)
NRG3 2 2 0 - - Visuomotor speed, processing speed, mental flexibililty, executive function, sustained attention (48, 49)
NRN1 1 1 0 - - General intellectual ability (50)
SNAP-25 1 1 0 - - Verbal memory, attention, executive function (51)
PRODH 1 0 1 1 - - (23, 52)
P2RX7 - - - 1 - - (23)
NPY - - - 1 - - (23)
NQO1 - - - 1 - - (23)
GST-1 - - - 1 - - (23)
GST-2 - - - 1 - - (23)
Serotonin 5HTT 2 1 1 1 - Executive function, attention (17, 21, 53)
HTR1A 1 1 0 1 - Theory of mind (17, 23, 54)
HTR2A 5 3 2 2 - Voluntary and involuntary attention, executive function, verbal fluency (1, 17, 23, 37, 55-57)
NET 2 0 2 - - - (6, 7)
System Gene N
Candidate Gene 
Studies Significant Cognitive Domains Reference
Positive Negative Multi-gene GWAS
Oligodendrocyte QKI 1 0 1 - - - (46)
MAG 1 1 0 - - Processing speed, visuomotor speed, attention (46)
CNP 1 0 1 - - - (46)
OLIG2 1 0 1 - - - (46)
ERBB4 1 0 1 1 - Verbal learning, abstraction, visuospatial memory (17, 46)
Glutamate GRIN2A 1 0 1 - - - (58)
GRIN2B 2 1 1 1 - Immediate and delayed recall (verbal memory) (1, 17, 58)
GRM1 - - - 1 - Attention, verbal learning, abstraction, visuospatial memory, spatial processing (17)
GRM3 1 1 0 1 - Enhanced performance (23, 58)
SLC1A2 - - - 1 - Attention, abstraction, spatial memory (17)
DAOA 1 1 0 1 1 Verbal memory (23, 59, 60)
GAD1 - - - 1 - - (23)
Ion channel CACNA1C 2 1 1 - - Logical memory (1, 61)
SCN2A - - - - 1 Cognitive ability (62)
Energy 
metabolism LYRM4 1 1 0 - - Verbal memory (63)
FARS1 1 1 0 - - Verbal memory (63)
ATP2C2 1 0 1 - - - (1)
Others ANK3 2 2 0 - - Working memory, verbal memory, attention (22, 64)
TCF4 1 1 0 - - Reasoning, problem-solving, attention-related tasks (65, 66)
CNNM2 1 0 1 - - Social cognition (67)
CSMD1 1 1 0 - 1 General cognitive ability,  memory cognition (68, 69)
STH 2 2 0 - - Executive function (25, 70)
ACT 1 0 1 - - - (71)
DCDC2 1 0 1 - - - (1)
DYX1C1 1 0 1 - - - (1)
KIAA0319 1 1 0 - - Verbal learning and recall (1)
NAGPA 1 0 1 - - - (1)
ZNF804A 4 3 1 - - Verbal learning and recall, verbal and spatial working memory, verbal episodic memory, visual memory (1, 72-74)
CLSTN2 1 0 1 - - - (1)
WWC1 2 0 2 - - - (1, 75)
ATRNL1 1 0 1 - - - (1)
C20orf196 1 0 1 - - - (1)
CRTC3 1 0 1 - - - (1)
DIP2C 1 0 1 - - - (1)
NFKBIL1 1 0 1 - - - (1)
System Gene N
Candidate Gene 
Studies Significant Cognitive Domains Reference
Positive Negative Multi-gene GWAS
PDE1C 1 0 1 - - - (1)
PKNOX1 1 0 1 - - - (1)
SPATA7 1 0 1 - - - (1)
ADCY8 2 0 2 - - - (1, 58)
CAMK2G 2 0 2 - - - (1, 58)
PRKACG 1 0 1 - - - (58)
PRKCA 1 1 0 - - Verbal memory (58)
HEY1 - - - - 1 Working memory (76)
MAD1L1 - - - - 1 Cognitive ability (77)
LSM1 - - - - 1 Cognitive ability (77)
CAM - - - - 1 Memory, attention (78)
 HLA-DQA1 - - - - 1 Attention (78)
RASGRF2 - - - - 1 Memory cognition (69)
PLCG2 - - - - 1 Memory cognition (69)
LMO1 - - - - 1 Memory cognition (69)
PRKG1 - - - - 1 Memory cognition (69)
EPO 1 1 0 - - Processing speed, short-term memory, and tasks requiring distinct fine motor component (79)
EPOR 1 1 0 - - Processing speed, short-term memory, and tasks requiring distinct fine motor component (79, 80)
RGS4 1 1 - 1 - Face and verbal memory speed (23)
PIP5K2A - - - 1 - - (23)
AKT1 - - - 1 - - (23)
LRRTM1 - - - 1 - - (23)
FGF2 - - - 1 - - Speed of information processing, attention/vigilance, verbal learning and memory, working memory, reasoning and problem solving, set shifting, and verbal comprehension (23)
FGFR1 - - - 1 - - (23)
GPM6A - - - 1 - - (23)
GABRA6 - - - 1 - - (23)
NOS1 1 1 - 1 - General cognitive ability, verbal and spatial working memory (23, 81)
RGS2 - - - 1 - - (23)
ROBO1 - - - 1 - - (23)
CHRM3 - - - 1 - - (23)
TBX1 - - - 1 - - (23)
ADRA2C - - - 1 - - (23)
FKBP5 - - - 1 - - Speed of information processing, attention/vigilance, verbal learning and memory, working memory, reasoning and problem solving, set shifting, and verbal comprehension (23)
DNMT3B - - - 1 - - Speed of information processing, attention/vigilance, verbal learning and memory, working memory, reasoning and problem solving, set shifting, and verbal comprehension (23)
CNR1 - - - 1 - - (23)
System Gene N
Candidate Gene 
Studies Significant Cognitive Domains Reference
Positive Negative Multi-gene GWAS
MTHFR 1 1 - 1 - IQ, spatial working memory, attentional flexibility and planning (23, 24)
MTR - - - 1 - - (23)
MTRR - - - 1 - - (23)
EHMT1 - - - 1 - - (23)
EHMT2 - - - 1 - - (23)
PRDM2 - - - 1 - - (23)
* This table did not include the genome-wide association study by Fernandes et al., 2013 (82) because no specific genes were identified.
Abbreviations for genes: serotonin transporter (5HTT), alpha-1-antichymotrypsin (ACT, also known as serine proteinase inhibitor 3 [SERPINA3]), adenylate cyclase (ADCY8), adrenoceptor alpha 2C 
(ADRA2C), v-akt murine thymoma viral oncogene homolog 1 (AKT1), ankyrin 3 (ANK3), ankyrin repeat and kinase domain containing 1 (ANKK1), ATPase, Ca++ transporting, type 2C, member 2 
(ATP2C2), attractin-like 1 (ATRNL1), brain-derived neurotrophic factor (BDNF), chromosome 20 open reading frame 196 (C20orf196), calcium channel, voltage-dependent, L type, alpha 1C (CACNA1C), 
cell adhesion molecules (CAM), calcium/calmodulin-dependent protein kinase II gamma (CAMK2G), cholinergic receptor, muscarinic 3 (CHRM3), calsyntenin 2 (CLSTN2), cyclin M2 (CNNM2), 2’,3’-cyclic 
nucleotide 3’-phosphodiesterase (CNP), cannabinoid receptor 1 (brain) (CNR1), catechol-O-methyltransferase (COMT), CREB regulated transcription coactivator 3 (CRTC3), CUB and Sushi multiple 
domains 1 (CSMD1), D-amino acid oxidase activator (DAOA), dopamine transporter (DAT, also known as SLC6A3), dopamine beta-hydroxylase (DBH), doublecortin domain containing 2 (DCDC2), DIP2 
disco-interacting protein 2 homolog C (Drosophila) (DIP2C), disrupted in schizophrenia 1 (DISC1), DNA (cytosine-5)-methyltransferase 3 beta (DNMT3B), dopamine D1 receptor (DRD1), dopamine D2 
receptor (DRD2), dopamine D3 receptor (DRD3), dopamine D4 receptor (DRD4), dopamine D5 receptor (DRD5), dystrobrevin binding protein 1 (DTNBP1), dyslexia susceptibility 1 candidate 1 (DYX1C1), 
euchromatic histone-lysine N-methyltransferase 1 (EHMT1), euchromatic histone-lysine N-methyltransferase 2 (EHMT2), erythropoietin (EPO), erythropoietin receptor (EPOR), v-erb-b2 avian 
erythroblastic leukemia viral oncogene homolog 4 (ERBB4), phenylalanyl-tRNA synthetase 2, mitochondrial (FARS2), fibroblast growth factor 2 (basic) (FGF2), fibroblast growth factor receptor 1 (FGFR1), 
FK506 binding protein 5 (FKBP5), gamma-aminobutyric acid (GABA) A receptor, alpha 6 (GABRA6), glutamate decarboxylase 1 (brain, 67kDa) (GAD1), glycoprotein M6A (GPM6A), glutamate receptor, 
ionotropic, N-methyl-D-aspartate, subunit 2A (GRIN2A), glutamate receptor, ionotropic, N-methyl-D-aspartate, subunit 2B (GRIN2B), glutamate receptor, metabotropic, 3 (GRM3), glutathione S-
transferase-1 (GST-1), glutathione S-transferase (GST-2), hairy/enhancer-of-split related with YRPW motif 1 (HEY1) , human leukocyte antigen (HLA), serotonin 1A receptor (HTR1A), serotonin 2A 
receptor (HTR2A), LIM domain only 1 (LMO1), leucine rich repeat transmembrane neuronal 1 (LRRTM1), LSM1 homolog, U6 small nuclear RNA associated (LSM1), MAD1 mitotic arrest deficient-like 1 
(MAD1L1), myelin-associated glycoprotein (MAG), MicroRNA 137 (MIRN137), mitochondrial pyruvate carrier 2 (MPC2), methylenetetrahydrofolate reductase (NAD(P)H) (MTHFR), 5-
methyltetrahydrofolate-homocysteine methyltransferase (MTR), 5-methyltetrahydrofolate-homocysteine methyltransferase reductase (MTRR), N-acetylglucosamine-1-phosphodiester alpha-N-
acetylglucosaminidase (NAGPA), norepinephrine transporter (NET, also known as SLC6A2), nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor-like 1 (NFKBIL1), nitric oxide 
synthase 1 (neuronal) (NOS1), neuropeptide Y (NPY), NAD(P)H dehydogenase, quinone 1 (NQO1), neuregulin 1 (NRG1), neuregulin 3 (NRG3), neurogranin (protein kinase C substrate, RC3) (NRGN), 
neuritin 1 (NRN1), 5’-nucleotidase, cytosolic II (NT5C2), oligodendrocyte lineage transcription factor 2 (OLIG2), purinergic receptor P2X, ligand-gated ion channel, 7 (P2RX7), prostate-specific transcript 
(non-protein coding) (PCGEM1), phosphatidylinositol-5-phosphate 4-kinase, type II, alpha (PIP4K2A), PBX/knotted 1 homeobox 1 (PKNOX1), phospholipase C, gamma 2 (PLCG2), protein phosphatise 1, 
regulator (inhibitor) subunit 1B (PPP1R1B), PR domain containing 2, with ZNF domain (PRDM2), protein kinase, cAMP-dependent, catalytic, gamma (PRKACG), protein kinase C, alpha (PRKCA), protein 
kinase, cGMP-dependent, type 1 (PRKG1),  proline dehydrogenase (oxidase) 1 (PRODH), quaking (QKI), Ras-specific guanine nucleotide-releasing factor 2 (RASGRF2), regulator of G-protein signalling 
2, 24kDa (RGS2), regulator of G-protein signalling 4 (RGS4), roundabout, axon guidance receptor, homolog 1 (Drosophila) (ROBO1), sodium channel, voltage-gated, type II, alpha subunit (SCN2A), 
serologically defined colon cancer antigen 8 (SDCCAG8), vesicular monoamine transporter 2 (SLC18A2), zinc finger, spermatogenesis associated 7 (SPATA7), saitohin (STH), synaptosomal-associated 
protein 25 (SNAP-25), T-box 1 (TBX1), transcription factor 4 (TCF4), translin-associated factor X (TRAX), SWIM-type containing 6 (ZSWIM6).
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Table 2. Molecular genetic studies of cognition across healthy to disease spectrum.*
System Gene Schizophrenia Cognition
Schizophrenia 
Disease Risk Healthy Dementia Cognitive Domains References
Dopamine COMT +/- +/- +/-9 +/- Executive function, theory of mind, reaction time, processing speed, attention
(1-20, 22-25, 83-
85)
DAT/SLC6A3 +/- +/- +/-9 +/-
- Speed of information processing, 
attention/vigilance, verbal learning and memory, 
working memory, reasoning and problem solving, 
set shifting, and verbal comprehension
(1, 7, 23, 26, 60, 
86, 87)
DRD1 + -9
- Speed of information processing, 
attention/vigilance, verbal learning and memory, 
working memory, reasoning and problem solving, 
set shifting, and verbal comprehension
(23)
DRD2 - +/- +/-9 - - (2, 22, 23, 85, 88-91)
DRD3 +/- +/- +/-1,9 -
Perseveration
- Speed of information processing, 
attention/vigilance, verbal learning and memory, 
working memory, reasoning and problem solving, 
set shifting, and verbal comprehension
(20, 22, 23, 26)
DRD4 + +/- + +/- Working memory, verbal fluency (5, 60, 85)
DRD5 + +/- -2 Visual voluntary attention (27)
DBH +/- +/- - + Immediate memory (20, 28, 92, 93)
SLC18A2 +/- +/- -1
- Speed of information processing, 
attention/vigilance, verbal learning and memory, 
working memory, reasoning and problem solving, 
set shifting, and verbal comprehension
(20)
ANKK1 - +/- -9 - (23)
PPP1R1B - +/- +/-9 - (23, 94)
Neuro DISC1 + +/- +/-9
Verbal fluency, verbal working memory, short- and 
long-term memory, short-term visual memory, 
visual search, attention
(1, 17, 23, 29-32)
DTNBP1 +/- +/- +/-9 Attention/vigilance domain, spatial working memory, IQ (23, 33-36)
BDNF +/- +/- +/-9 +/-
Voluntary and involuntary attention, verbal 
memory, visuospatial skills, working memory
- Speed of information processing, 
attention/vigilance, verbal learning and memory, 
working memory, reasoning and problem solving, 
set shifting, and verbal comprehension
(1, 23, 37-45, 85)
NRG1 + +/- -3,9 + Processing speed, visuomotor speed, attention, long-term episodic memory, short-term memory (17, 23, 46, 47)
NRG3 + +/- + Visuomotor speed, processing speed, mental flexibililty, executive function, sustained attention (48, 49, 95)
NRN1 + +/- -3 General intellectual ability (50)
SNAP-25 + +/- +1 + Verbal memory, attention, executive function (51, 96)
PRODH - +/- +/-9 - (23, 52, 97)
P2RX7 - - -9 - - (23, 98)
NPY - +/- -9 - - (23)
NQO1 - - -9 +/- - (23)
GST-1 - -9 - (23)
GST-2 - -9 - (23)
Serotonin 5HTT/SLC6A4 +/- +/- + +/- Executive function, attention (17, 21, 53, 99)
HTR1A + +/- Theory of mind (17, 54)
HTR2A +/- +/- -9 +4/- Voluntary and involuntary attention, executive function, verbal fluency
(1, 17, 23, 37, 55-
57, 83)
NET/SLC6A2 - - - (6, 7)
Oligodendrocyte QKI - - -5 + - (46, 100)
MAG + +/- +5 Processing speed, visuomotor speed, attention (46)
CNP - +/- -5 - (46)
OLIG2 - +/- +5 +4/- - (46, 101)
ERBB4 - +/- +5 + Verbal learning, abstraction, visuospatial memory (17, 20, 46)
Glutamate GRIN2A - +/- + - (58)
GRIN2B +/- +/- + +/- Immediate and delayed recall (verbal memory) (1, 17, 58)
GRM1 + + Attention, verbal learning, abstraction, visuospatial memory, spatial processing (17, 21, 86)
GRM3 + +/- +/-9 Enhanced performance (23, 58, 87)
SLC1A2 + +/- Attention, abstraction, spatial memory (17)
DAOA + +/- +6/-9 +4 Verbal memory (23, 59, 60)
GAD1 - +/- -9 - (23)
Ion channel CACNA1C +/- + -3 + Logical memory (1, 61, 88, 89)
SCN2A + -2 Cognitive ability (g) (62, 90)
Energy 
metabolism LYRM4 + Verbal memory (63)
FARS1 + Verbal memory (63)
ATP2C2 - - (1)
Others ANK3 + +/- +/-3 +/- Working memory, verbal memory, attention (64, 91, 92, 102)
TCF4 + +/- +7 Reasoning, problem-solving, attention-related tasks (65, 66)
CNNM2 - + - Social cognition (67, 103)
CSMD1 + + + General cognitive ability,  memory cognition (68, 69, 104, 105)
STH + - +/- Executive function (25, 70)
ACT - - + - (71, 106)
DCDC2 - - - (1)
DYX1C1 - - (1)
KIAA0319 + Verbal learning and recall (1)
NAGPA - - (1)
ZNF804A +/- +/- +/-
Verbal learning and recall, verbal and spatial 




CLSTN2 - +/- - (1, 111, 112)
WWC1 - + +/- +/- - (1, 75, 113-116)
ATRNL1 - - (1)
C20orf196 - - (1)
CRTC3 - - (1)
DIP2C - - (1)
NFKBIL1 - - - (1)
PDE1C - - (1)
PKNOX1 - - (1)
SPATA7 - - (1)
ADCY8 - - (1, 58)
CAMK2G - - - (1, 58)
PRKACG - - (58)
PRKCA + +/- + Verbal memory (58, 117)
HEY1 + Working memory (76)
MAD1L1 + + Cognitive ability (77, 118)
LSM1 + +/- Cognitive ability (77, 119, 120)
CAM + Memory, attention (78)
 HLA-DQA1 + - +/- (A2) Attention (78, 121-123)
RASGRF2 + Memory cognition (69)
PLCG2 + Memory cognition (69)
LMO1 + Memory cognition (69)
PRKG1 + - +/- Memory cognition (69, 124, 125)
EPO + Processing speed, short-term memory, and tasks requiring distinct fine motor component (79)
EPOR + Processing speed, short-term memory, and tasks requiring distinct fine motor component (79)
RGS4 +/-1 +/- +1/-9 - - (23, 80, 126)
PIP5K2A - +/- -9 - (23)
AKT1 - +/- -9 - (23)
LRRTM1 - + -9 - (23, 127)
FGF2 + - -2/-9
- Speed of information processing, 
attention/vigilance, verbal learning and memory, 
working memory, reasoning and problem solving, 
set shifting, and verbal comprehension
(23)
FGFR1 - -9 - (23)
GPM6A - + -9 - (23, 128)
GABRA6 - +/- -9 - (23)
NOS1 +/- +/- +/-2,9 +/- General cognitive ability, verbal and spatial working memory (23, 81)
RGS2 - + -9 - (23, 129)
ROBO1 - -9 - (23)
CHRM3 - -9 - (23)
TBX1 - +/- -9 - (23)
ADRA2C - -9 - (23, 130)
FKBP5 + - -9
- Speed of information processing, 
attention/vigilance, verbal learning and memory, 
working memory, reasoning and problem solving, 
set shifting, and verbal comprehension
(23)
DNMT3B + + -9 +/-
- Speed of information processing, 
attention/vigilance, verbal learning and memory, 
working memory, reasoning and problem solving, 
set shifting, and verbal comprehension
(23, 131, 132)
CNR1 - +/- -9 - (23, 133)
MTHFR +/- +/- -9 +/- - (23, 24, 133-137)
MTR - + -9 +/- - (23, 134)
MTRR - - -9 - (23, 134, 138, 139)
EHMT1 - -9 - (23)
EHMT2 - - -9 - (23)
PRDM2 - -9 - (23)
* The list of genes in this table has been cross-referenced with the genetic databases in schizophrenia www.alzgene.org (100) and Alzheimer’s 
disease www.szgene.org (101) and updated with references from PubMed for schizophrenia risk genes, dementia risk genes, and genes affecting 
normal cognition.
“+” indicates previous significant association(s), “-” indicates prior negative association(s), and “+/-” indicates previous positive and negative 
associations.
1 This study reported a significant association between SNP(s) across this gene and cognitive function(s) in the combined psychosis and healthy 
control sample.
2 This study detected a significant association between SNP(s) across this gene only in schizophrenia patients and their unaffected relatives but not in 
healthy controls.
3 This study found significant association between SNP(s) across this gene only in schizophrenia patients but not in healthy controls.
4 This study found significant association between this gene and psychosis in patients with Alzheimer’s disease.
5 This study reported significant associations for MAG in schizophrenia patients and healthy controls but in different cognitive domains and for 
OLIG2 and ERBB4 in only healthy controls; QKI and CNP were not significant in either sample.
6 This study found significant association between DAOA and cognitive function regardless of disease status (psychosis patients and healthy controls).
7 This study found significant association between TCF4 and cognitive function in schizophrenia patients and healthy controls but opposite alleles 
associated with cognitive better performance.
8 This study with two independent samples found significant associations between NOS1 and cognitive function in Irish controls but not in Irish 
schizophrenia patients, and German schizophrenia patients but not controls.
9 This study found significant association between SNP(s) across this gene only in schizophrenia patients but not in their unaffected relatives or 
healthy controls.
Supplementary Table 1. Molecular genetic studies of cognitive deficits in schizophrenia.
Gene Chromosome Polymorphism Sample Cognition Result Reference
343 schizophrenia 
patients




 Significant effects on 
processing speed and 
executive functions
 COMT × STH Q7R 
interaction on 
executive functions 
with COMT Val/Val 
and STH R carriers 
performing worse










Symbol and Symbol 
Search subtests, D-
KEFS
















 Val homozygotes 
with worse cognitive 
performance in the 
absence of childhood 
adversity
 Val homozygotes and 
history of abuse with 
better executive 
function
 Met carriers and 
history of physical 
abuse with worse 
positive symptoms
 Met carriers and 
history of emotional 
Green et al., 
2014 (3)
Gene Chromosome Polymorphism Sample Cognition Result Reference

















WAIS-III to assess 
IQ
 COMT × MTHFR 
rs1801133 interaction 
on spatial working 
memory (P=0.048) 
and planning 
(P=0.026) in cases 
and controls
 COMT Val/Val and 
MTHFR C/C 
individuals with 






(P=0.025) in both 
groups
 COMT × MTHFR 
interaction with IQ 
(P=0.035), worse 
performance with 
COMT Met carriers 














 No association Lopez-
Garcia et 
al., 2013 (5)




disorder, 5 brief 
psychotic disorder, 





and 67 healthy 
controls
HVLT-R, BVMT-R, 
DPX task (modified 











task, TASA corpus, 
 No association Nicodemus 
et al., 2013 
(6)
209 schizophrenia 
and 172 healthy 
people
ToM: second-order 
false belief, faux pas 
stories
 No association in 
schizophrenia
 Met allele in females 
(schizophrenia and 
controls) with worse 
performance than 






bipolar I disorder, 




sample task), 4 tasks 
testing verbal and 
visuospatial working 
memory
 No association Zilles et al., 
2012 (8)







13 psychosis not 
otherwise 











Stroop 1 words, 
Stroop 2 colours, 
CPT, TAVEC (total 
learning, short term 





 No association Bombin et 
al., 2008 (9)
Meta-analysis:
1910 patients and 
controls
 Szöke et al. 
(2006)
 Rybakowski et 
al. (2006a)
 Minzenberg et 







disorder, and 60 
unrelated normal 
controls)
WCST  No association in 
schizophrenia
 Met/Met genotype 
with better 
performance than 
Val/Val in healthy 
controls (d=0.29, 





Gene Chromosome Polymorphism Sample Cognition Result Reference
 Ho et al. (2005)
 Galderisi et al. 
(2005)
 Bruder et al. 
(2005; healthy 
volunteers)
 Rosa et al. 
(2004)








 Joober et al. 
(2002)
 Bilder et al. 
(2002)





responders to one 
adequately dosed 
antipsychotic for 3 
months
 Placebo vs. 
active (both with 
SRT)






Val/Val on placebo 
(P=0.01)
Bosia et al., 
2007 (11)
Gene Chromosome Polymorphism Sample Cognition Result Reference
150 schizophrenia 
patients, 83 
relatives, and 118 
mentally healthy 
subjects with no 
















haplotype with best 
results on working 
memory and Met-A 











disorder, and 158 
healthy controls or 
relatives)
TMT (TMTA and 
TMTB), WCST




patients (60 males; 
mean age 27 years; 
mean age at onset 
23 years)
WCST  Val/Val genotype 
with better results on 
all domains of WCST 
in males (P=0.044) 
but worse in females 
(P=0.042)
Rybakowski 
et al., 2006 
(14)






 No association Ho et al., 
2005 (15)
Gene Chromosome Polymorphism Sample Cognition Result Reference
male; mean age 
26.5 years) and 84 
healthy volunteers 
(40.48% male; 





(56 with deficit 
schizophrenia and 





 Significant main 
effect accounting for 




 Val/Val genotype 
with worse WCST 
and CPT-AX when 
compared to Met 
carriers
 Val/Val genotype 
with worse NES 
motor scores than 






26 (18 males; 25 
Caucasians and 1 
Hispanic; mean 






 Val with slower 
reaction time when 
compared to Met 
homozygotes 
(P<0.05)
 Met homozygotes 
with greater accuracy 
for imitation but not 
reversal response, 
Nolan et al., 
2004 (17)
Gene Chromosome Polymorphism Sample Cognition Result Reference
lower trials to 
criterion (P<0.05), 
and greatest 












disorder, 5 brief 
psychotic disorder, 
2 delusional 




WCST  Val/Val genotype 
with more 
perseverative errors 
in healthy siblings 










(59 males; mean 
age 37 years), 108 
siblings (46 males; 
mean age 37 
years), and 68 
controls (41 males; 
N-back task, CPT 
“1-9 Distractibility 
Version”, WAIS-R
 Val/Val genotype 
with lowest (n-back) 
and slowest 
performance in 
controls, siblings and 
patients






Gene Chromosome Polymorphism Sample Cognition Result Reference
mean age 35 years)
104 DSM-IV 
schizophrenia 
patients and 96 
unrelated healthy 
volunteers (94 




WCST  Met allele with better 
WCST performance 
in the combined 
patient and control 




















>2 years and 









Paragraph Recall I, 
Paragraph Recall II, 
Word list Learning 
I, Word List 





 Met allele with better 
performance in the 
processing speed and 
attention domain but 
not with executive 
and visuoperceptual 
functions, declarative 
verbal learning and 
memory, simple 










(138 males; mean 
WCST, WAIS-R  Accounted for 4.1% 




Egan et al., 
2001 (22)
Gene Chromosome Polymorphism Sample Cognition Result Reference
age 36.1 years), 
219 unaffected 
siblings (97 males; 
mean age 35.6 
years), and 55 
controls (23 males; 
mean age 33.9 
years)














and 468 controls; 
119 north Indian 
trio replication 
sample
TMT for 260 cases 
and 302 parents
 No association Kukshal et 
al., 2013 
(23)








task, TASA corpus, 
 No association Nicodemus 
et al., 2013 
(6)
rs403636 601 Indian DSM-
IV schizophrenia 
case-parent trios 
and 468 controls; 
119 north Indian 
trio replication 
sample
TMT for 260 cases 
and 302 parents






VNTR * 32 ICD-10 
schizophrenia, 22 
bipolar I disorder, 
26 OCD, and 20 
Sternberg paradigm 
(delayed match-to-
sample task), 4 tasks 
testing verbal and 




Zilles et al., 
2012 (8)
Gene Chromosome Polymorphism Sample Cognition Result Reference








(corrected for disease 






patients (60 males; 
mean age 27 years; 
mean age at onset 
23 years)
WCST  No association Rybakowski 
et al., 2006 
(14)
VNTR *








 Ser/Ser genotype 
with fewer categories 





















 Significant difference 
for executive 
functioning domain 




Gene Chromosome Polymorphism Sample Cognition Result Reference
bipolar disorder, 
13 psychosis not 
otherwise 




symptoms) and 90 
healthy controls
Stroop 1 words, 
Stroop 2 colours, 
CPT, TAVEC (total 
learning, short term 












and 468 controls; 
119 north Indian 
trio replication 
sample
TMT for 260 cases 
and 302 parents
 No association Kukshal et 
al., 2013 
(23)
Not provided 209 schizophrenia 
patients and 172 
healthy people
Second-order false 
belief and faux pas 
stories
 No associations Alfimova et 
al., 2013 (7)
DRD2 11q23.2






13 psychosis not 
otherwise 










Stroop 1 words, 
Stroop 2 colours, 
CPT, TAVEC (total 
learning, short term 




 No association Bombin et 
al., 2008 (9)
Gene Chromosome Polymorphism Sample Cognition Result Reference
healthy controls WCST




relatives, and 118 
mentally healthy 
subjects with no 










haplotype with best 
results on working 
memory and Met-A 











DRD5 4p16.1 CT/GT/GA 
microsatellites
152 schizophrenia 
patients (81 males; 
mean age 34.7 
years) and 81 
mentally healthy 
individuals without 
family history of 
schizophrenia (54 




spoken words with 2 
series of 10 words), 
long-term memory 
(16 words and to 
draw picture for 
each word, verbal 
fluency (generation 





counting from 200 
to 100 by 2 and 5)
 2 allele 7 with lower 
word generation 
(visual voluntary 
attention) than 1 
allele 7 in 
schizophrenia 





DBH 9q34.2 5’–Ins/Del 195 DSM-IV first-
episode psychosis 
RBANS – Form A  19bp Del allele and 
Del/Del homozygous 
Hui et al., 
2013 (26)
Gene Chromosome Polymorphism Sample Cognition Result Reference
schizophrenia 
patients (drug-




score in patients 
(P<0.05) but not in 
healthy controls
rs6271 601 Indian DSM-
IV schizophrenia 
case-parent trios 
and 468 controls; 
119 north Indian 
trio replication 
sample
TMT for 260 cases 
and 302 parents










and 468 controls; 
119 north Indian 
trio replication 
sample
TMT for 260 cases 
and 302 parents
















task, TASA corpus, 
 rs12133766 with 
verbal fluency in 
male probands 
(P=0.049) and 
healthy males only 
(P=0.018)
Nicodemus 















& TMT-B (rapid 
visual search), 
 rs2255340 genotype 
with rapid visual 
search (P=0.002) and 
verbal working 
memory (P=0.010), 
explaining 3-4% of 
the variance
Burdick et 
al., 2005  
(27)




















parents, and 238 
healthy controls
WMS-R, CVLT, 
WCST, N back, 
CPT, letter fluency, 
WAIS-R, WRAT






in schizophrenia and 
lower WCST 
category scores 












236 DSM-III-R or 
DSM-IV 
schizophrenia 
subjects (6 MZ and 
1 DZ concordant 
for schizophrenia, 
20 MZ and 32 DZ 
discordant for 
schizophrenia, and 
28 MZ and 31 DZ 
normal twin pairs)




reduced gray matter 
















































of 215 families 
with 1437 
individuals and 
400 affected; 390 















patients and 119 
healthy subjects





CPT-DS, span of 
apprehension








Baek et al., 
2012 (31)





domain after multiple 
testing correction 
whereas rs2619539 
did not survive 
correction in 
combined patient and 
healthy subjects
39 tagging SNPs (1 













508 (371 males) 
European (>75% 
Anglo-Irish) DSM-
IV and ICD-10 
schizophrenia 
patients (155 with 
pervasive cognitive 
deficit and 121 
with relatively 
spared cognition) 
and  172 controls 
(102 males)
NART, SILS, visual 
CPT-DS and CPT-
IP, FAS version of 
COWAT, RAVLT, 
IT task, EHI
 No association with 
schizophrenia 
diagnosis or any 
cognitive measures





















rs909706 183 Caucasian WAIS-R, CPC-I/P,  CTCTAC risk Burdick et 










TMT A & B
haplotype with 





(972 Met carriers 





























task, TASA corpus 
 No association Nicodemus 
et al., 2013 
(6)
BDNF 11p13 Val66Met (rs6265)
657 DSM-IV 
schizophrenia 
















 Schizophrenia Met 
carriers with 
Zhang et al., 
2012 (36)
Gene Chromosome Polymorphism Sample Cognition Result Reference
attention impairment
 Val allele with better 
visuospatial/construct






patients and 63 
healthy controls
WAIS-R (verbal and 
performance IQ), 
WMS-R, WCST
 Schizophrenia Met 
carriers showed 
higher percentage of 
WCST perseverative 
errors (P=0.007), 
especially in males 
(P=0.014) but no in 
females (P=0.09)
Lu et al., 
2012 (37)
51 male DSM-IV 
schizophrenia 
patients who had 
committed 















recall, WCST NCC, 
WCST perseverative 
responses %, WCST 
perseverative errors 
%











 Val/Val genotype 
with higher scores of 






Gene Chromosome Polymorphism Sample Cognition Result Reference
Met with lower 
scores of voluntary 
attention and higher 
scores of involuntary 
attention























patients and 144 
healthy volunteers
RAV, WAIS-R  Met allele carriers 









patients (66 males; 
mean age 27 years; 
mean age of onset 
23 years) and 111 
DSM-IV/ICD-10 
bipolar disorder 
patients (37 males; 
mean age 43 years; 
WCST, N-back test  No association with 
WCST
 Val/Val genotype 
with higher correct 
reactions (working 
memory) in N-back 
test
Rybakowski 
et al., 2006 
(42)
Gene Chromosome Polymorphism Sample Cognition Result Reference
mean age of onset 
31 years)
203 schizophrenia 







fluency, and WCST 
perseverative errors
 Individuals with one 
or two Met allele(s) 
had lower abilities to 
perform tasks of 
learning and memory
Egan et al., 
2003 (43)
SNAP-25 20p12-p11.2 MnlI (rs3746544) 66 major psychosis 
patients, 75 

















families with 167 
first-episode 
patients (80 males)
Stroop test, TMT 
(TMTA and 










patients and 60 
healthy controls
EXIT, letter number 

















speed and attention in 
schizophrenia, 
visuomotor speed 




et al., 2013 
(46)
Gene Chromosome Polymorphism Sample Cognition Result Reference
MAG rs2301600 and 
rs720309 in 
schizophrenia with 














 Allele 0 of 478B14-
848 with long-term 
episodic memory in 
schizophrenia
 Allele 0 of 420M9-






rs6584400 358 DSM-IV 
schizophrenia (214 
males; average age 
35.78 years) and 
111 DSM-IV 
bipolar disorder 
(55 males; average 




TMT (TMTA and 
TMTB), CSP-DS




schizophrenia but not 
bipolar disorder 
(P=0.885)
 A carriers with faster 
TMTA and TMTB in 
schizophrenia 
(P<0.05) and bipolar 
disorder (P<0.05)






Meier et al., 
2013 (48)
NRG3 10q22-q23
rs6584400 411 European Battery of  No association with Morar et al., 








and 148 with 
relatively spared 

















 rs6584400 and 




 No effect on general 
intelligence or verbal 
memory
 A allele of rs6584400 
(=0.523, 95% CI 
0.070-0.976, 
P=0.025) and G 
allele of rs10883866 





performance task and 












508 (371 males) 
Australian (>75% 
Anglo-Irish) DSM-
IV and ICD-10 
schizophrenia 
patients (155 with 
pervasive cognitive 




 No association with 
schizophrenia 
diagnosis
 G allele of rs1475157 
(P=0.005, P=0.047 
after multiple testing 
correction) with 

















and  172 controls 
(102 males)
 G allele rs9405890 
(P=0.001, P=0.027 
after multiple testing 
correction) with 
higher SILS scores in 
schizophrenia
 G-A haplotype of 
rs1475157-
rs9405890 with 
lower current SILS 






bipolar I disorder, 




sample task), 4 tasks 
testing verbal and 
visuospatial working 
memory







WCST, CPT  High activity long 




Bosia et al., 
2010 (51)






PANSS) to one 
WAIS-R, WCST, 
BACS, ToM Picture 
Sequencing Task
 CC genotype and 
higher ToM task 
score (F=4.13, d.f.=2, 
P=0.019)
Bosia et al., 
2011 (52)
Gene Chromosome Polymorphism Sample Cognition Result Reference
adequately dosed 












task, TASA corpus, 
 No association Nicodemus 










 T allele with more 




lower scores of 
voluntary attention 







patients (47 males; 
mean duration of 
illness 6.7 years)
BPRS, CPT, WCST  T allele with lower 
hit rate in CPT
 T/C genotype with 
more commission 
errors in CPT and 
fewer correct 
responses in WCST









 A2/A2 homozygotes 
with lower verbal 













 Trend between T/C 
Chen et al., 
2001 (55)
Gene Chromosome Polymorphism Sample Cognition Result Reference
schizophrenia 
patients (334 
males; mean age 










test (“colour task” 
and “colour-word 
task”), WAIS
genotype and better 












disorder, and 158 
healthy controls or 
relatives)
TMT (TMTA and 
TMTB), WCST





1287A/G * 124 DSM-IV 
schizophrenia 
patients (60 males; 
mean age 27 years; 
mean age at onset 
23 years)
WCST  No association Rybakowski 
et al., 2006a 
(14)








task, TASA corpus, 
 No association Nicodemus 
et al., 2013 
(6)
CACNA1C 12p13.3
rs1006737 202 Japanese WMS-R, WAIS-R,  A allele carriers with Hori et al., 
Gene Chromosome Polymorphism Sample Cognition Result Reference
DSM-IV 
schizophrenia from 
a total sample of 
552 patients (304 
males; mean age 
43.7 years) and 
706 controls
WCST worse logical 
memory performance 
in schizophrenia 












Irish) DSM-IV and 
ICD-10 
schizophrenia 





















haplotype with poor 
memory and high 













patients and 60 
healthy controls
EXIT, letter number 














and ERBB4 rs839523 
with processing 
speed, visuomotor 
speed and attention in 
Voineskos 
et al., 2013 
(46)
Gene Chromosome Polymorphism Sample Cognition Result Reference
schizophrenia, 
visuomotor speed 
and verbal memory 
in controls (P=0.02)
 MAG rs2301600 and 
rs720309, and NRG1 
SNP8NRG221533 in 
schizophrenia with 
the same tasks as 
above (P=0.01)




 No association in 
schizophrenia
 OLIG2 rs1059004 
and ERBB4 rs839253 
predicting 
performance on tasks 




speed and dexterity, 
and working memory 








naïve) and 42 
healthy subjects 
(sex and age-
N-back task  Schizophrenia 




 rs10994336 T/T 
genotype with lower 
Zhang et al., 
2014 (58)
Gene Chromosome Polymorphism Sample Cognition Result Reference
matched) accuracy rate and 
more reaction time at 































Span for working 
memory) WAIS-III 
(IQ, Digit Span for 
working memory, 
Digit Symbol for 
processing speed, 
Block Design for 
reasoning and 
problem solving), 
TMTA and TMTB, 












 Identical pattern 









 C carriers with lower 







Gene Chromosome Polymorphism Sample Cognition Result Reference
rs2958182 580 ICD-10 
schizophrenia 





backward digit span 
tasks, ANT, Stroop 
task, DPX task, N-
back task
 Risk (T) allele with 
better performance 
on cognitive tasks in 
schizophrenia 
patients but with 
worse performance in 
controls
 Genotype and disease 
(P=0.011), attention-






Zhu et al., 
2013 (60)
CNNM2 10q24.32 rs7914558 400 schizophrenia 




function and social 
cognition
 No association
 Dosage effect of risk 
allele with 






Rose et al., 
2014 (61)
CSMD1 8p23.2 rs10503253 378 Irish DSM-IV 
schizophrenia 




patients and 533 
healthy controls








 Schizophrenia risk A 
allele with poorer 
performance in 
general cognitive 
ability and memory 













(verbal and visual 
episodic memory 
with logical memory 
and faces subtests), 
CANTAB (letter 
number sequencing 
task and spatial 
working memory 
task, WMS-R (Digit 
Span and Spatial 
Span score), N-back 
task, CPT 3-7 
version
Q7R * 343 schizophrenia 
patients




 Significant effects on 
executive functions
 COMT rs4680 × STH 
interaction on 
executive functions 
with COMT Val/Val 
and STH R carriers 
performing worse
Bosia et al., 
2014 (1)
STH 17q21.1








Bosia et al., 
2012 (63)
Gene Chromosome Polymorphism Sample Cognition Result Reference
reduction in 
PANSS) to one 
adequately dosed 








 G allele with poor 
performances on 
WCST (P=0.044)
2 Affymetrix chips 













disorder, and 7 
schizophreniform 






(Digit Span for 
auditory attention 






(verbal learning and 
memory), TMTA 
and TMTB (visual-
motor speed and 
executive control)
 GCGGC carrier with 
better performance 
on semantic fluency 
than non-carriers 
regardless of disease 
status
Opgen-





93 Irish DSM-IV 
schizophrenia 
patients (from 373 




Learning task, IED), 
CPT, N-back task, 
WTAR









Gene Chromosome Polymorphism Sample Cognition Result Reference
(P=0.015)
 6.4% variance 
explained verbal 
memory performance






14q32.1 Ala-15Thr * 175 DSM-IV 
schizophrenia 
inpatients and 114 
healthy controls




 No significant 
difference with 
cognitive impairment




 Carriers of EPO 
rs1617640 and EPOR 
STR(GA)n low 
repeat sum showed 
superior performance 
in cases
 No differences for 













Dotting and Tapping 
from Mac-Quarrie 








5q34 rs17070145 544 (166 probands 
with schizophrenia 
or bipolar disorder, 
201 unaffected 
relatives, and 177 
healthy controls)
WMS-R for episodic 
memory, immediate 






 Nominal significant 
for both immediate 







Gene Chromosome Polymorphism Sample Cognition Result Reference
healthy controls only 
(P=0.025)
 Trend for delayed 
visual memory in 
patients (P=0.05)
ATP2C2 16q24.1 rs2303853  No association
DCDC2 6p22.1 rs2274305  No association




 rs807534 with verbal 
learning and recall in 
female siblings 
(P=0.041) and 
healthy females only 
(P=0.032)












ATRNL1 10q26 rs10885721  No association
C20orf196 20p12.3 rs1699233  No association



















et al., 2013 
(6)
Gene Chromosome Polymorphism Sample Cognition Result Reference
PKNOX1 21q22.3 rs234781  No association












 rs1366842 with 
verbal learning and 
recall in male 
probands (P=0.033) 
and healthy males 
only (P=0.042)
Nicodemus 





and 200 healthy 
controls
Theory of Mind 
with “Eyes of the 






 No association for 
Theory of Mind










patients and 184 
healthy controls



















patients with lower 
scores on all memory 
Hashimoto 
et al., 2010 
(70)
Gene Chromosome Polymorphism Sample Cognition Result Reference
indices than controls
 Genotype effect in 
schizophrenia 
patients (P=0.018) 
but not in controls
 T/T genotype with 
significantly lower 
performance on 
visual memory than 




samples: 297 Irish 
DSM-IV 
schizophrenia 




patients and up to 
1472 controls






CANTAB for verbal 
and spatial working 
memory, and CPT 
for vigilant attention
German: WAIS-R 
for IQ, WMS-R for 
verbal and visual 
episodic memory, 
WAIS-R and WMS-
R for working 
memory, and CPT 
for vigilant attention
 Irish: AA genotype 
with better verbal 
(P=0.046) and spatial 
(P=0.045) working 
memory, AA and AC 
genotypes with better 
verbal episodic 
memory (AA: 
P=0.01; AC: P=0.02) 
in schizophrenia 
patients
 German: AA 










 No association Nicodemus 
et al., 2013 
Gene Chromosome Polymorphism Sample Cognition Result Reference
patients, 164 
unaffected 
siblings, and 307 
healthy controls
task, TASA corpus (6)
rs263249 336 European 
(>75% Anglo-
Irish; 80% males; 
mean age 33.9 
years; mean length 




patients and  172 
normal (59% 






version of COWAT, 
RAVLT, IT task
 No association Jablensky et 
al., 2011 
(72)









 No association Nicodemus 







Irish; 80% males; 
mean age 33.9 
years; mean length 






version of COWAT, 
RAVLT, IT task









Gene Chromosome Polymorphism Sample Cognition Result Reference
schizophrenia 
patients and  172 
normal (59% 
males; mean age 
40.7 years) 
controls









 No association Nicodemus 
et al., 2013 
(6)
CAMK2G 10q22
rs11000787 336 European 
(>75% Anglo-
Irish; 80% males; 
mean age 33.9 
years; mean length 




patients and  172 
normal (59% 






version of COWAT, 
RAVLT, IT task













Irish; 80% males; 
mean age 33.9 
years; mean length 










Gene Chromosome Polymorphism Sample Cognition Result Reference
PRKCA 17q22-q23.2 rs8074995 years) DSM-IV 
and ICD-10 
schizophrenia 
patients and  172 
normal (59% 
males; mean age 
40.7 years) 
controls
















least 2 affected 
first-degree 












for attention, Penn 
Word Memory Test 
for verbal memory, 
Penn Face Memory 
Test for face 
memory, Visual 
Object Learning 
Test for spatial 
memory, Judgment 






 rs10917670 with face 
and verbal memory 









smaller squares for 
sensorimotor 
dexterity
NOS1 12q24.22 rs6490121 2 independent 
samples: 349 Irish 
DSM-IV 
schizophrenia 




patients and 1344 
controls
Irish: WAIS-III for 
general cognitive 
functioning (IQ), 
WMS-III for verbal 
and visual episodic 
memory, WMS-III 
and CANTAB-
Expedio Version for 
verbal and spatial 
working memory, 
and CPT for 
attentional control
German: WAIS-R 
for IQ, WMS-R for 
verbal and visual 
episodic memory, 
WMS-R and N-back 
task for verbal and 
spatial working 
memory, and CPT 
for attentional 
control
 GG genotype with 
poorer verbal IQ in 
both Irish (P=0.04) 
and German 
(P=0.01) cases and 
controls
 GG genotype with 
poorer verbal 
(P<0.001) and spatial 
(P=0.008) working 
memory in Irish 





score in patients 





MTHFR 1p36.22 rs1801133 (C677T) 90 DSM-IV 
schizophrenia 





Memory and Spatial 
 MTHFR × COMT 













WAIS-III to assess 
IQ
and planning 
(P=0.026) in cases 
and controls
 COMT Val/Val and 
MTHFR C/C 
individuals with 






(P=0.025) in both 
groups
 COMT × MTHFR 
interaction with IQ 
(P=0.035), worse 
performance with 
COMT Met carriers 













Candidate genes 152 SNPs in 43 
genes (quality 
controlled from 179 
SNPs)





parents and their 
siblings, and 590 
unrelated controls
WAIS-III (Digit 




Word Learning Task 





 DRD1 rs265981 
allele G (P=0.010), 
DRD3 rs6280 allele 
C (P=0.031), 
SLC6A3 rs456082 
allele C, rs463379 
allele G, rs464049 
allele C, BDNF 
rs988748 allele G, 
FGF2 rs7700205 






































Design for reasoning 
and problem 
solving, Reponse-








rs363393 allele A, 
rs363338 allele C, 
rs363227 allele T, 
FKBP5 rs1334894 
allele G, DNMT3B 
rs2424913 allele T, 
and rs406193 allele C 
with worse cognitive 
performance in 
patients
 SLC18A2 rs363227 
allele T with poorer 
cognitive functioning 
in siblings (P=0.04) 





































spatial memory (i.e., 
ERBB4, GRM1, 





















































(75 families; 37% 
males; mean age 



























false alarms, CPT 











































~900 K SNPs 
(Affymetrix 6.0) 
and ~770 K SNPs 































WASI, Alice Heim 
4, Mill Hill 
Vocabulary A and 
B, Cattell and 
Cattell Cultural Fair 
intelligence tests, 
Finnish Defesnse 
Forces Basic Ability 





 No genome-wide 
significance
 Schizophrenia 
patients with lower 
general cognitive 
ability than healthy 
controls





alleles with lower 
cognitive ability
 LSM1 rs16887244 




allele with higher 
cognitive ability
Lencz et al., 
2014 (79)















 Strongest genetic 
enrichments for 
performance in a 
colour-interference 



































 Increased CAM 
pathway polygenic 
risk scores with 
poorer performance 








































Xiang et al., 
2012 (82)
* rs number not available.
Abbreviations for genes: serotonin transporter (5HTT), alpha-1-antichymotrypsin (ACT, also known as serine proteinase inhibitor 3 
[SERPINA3]), adenylate cyclase (ADCY8), adrenoceptor alpha 2C (ADRA2C), v-akt murine thymoma viral oncogene homolog 1 
(AKT1), ankyrin 3 (ANK3), ankyrin repeat and kinase domain containing 1 (ANKK1), ATPase, Ca++ transporting, type 2C, member 2 
(ATP2C2), attractin-like 1 (ATRNL1), brain-derived neurotrophic factor (BDNF), chromosome 20 open reading frame 196 
(C20orf196), calcium channel, voltage-dependent, L type, alpha 1C (CACNA1C), cell adhesion molecules (CAM), 
calcium/calmodulin-dependent protein kinase II gamma (CAMK2G), cholinergic receptor, muscarinic 3 (CHRM3), calsyntenin 2 
(CLSTN2), cyclin M2 (CNNM2), 2’,3’-cyclic nucleotide 3’-phosphodiesterase (CNP), cannabinoid receptor 1 (brain) (CNR1), 
catechol-O-methyltransferase (COMT), CREB regulated transcription coactivator 3 (CRTC3), CUB and Sushi multiple domains 1 
(CSMD1), D-amino acid oxidase activator (DAOA), dopamine transporter (DAT, also known as SLC6A3), dopamine beta-hydroxylase 
(DBH), doublecortin domain containing 2 (DCDC2), DIP2 disco-interacting protein 2 homolog C (Drosophila) (DIP2C), disrupted in 
schizophrenia 1 (DISC1), DNA (cytosine-5)-methyltransferase 3 beta (DNMT3B), dopamine D1 receptor (DRD1), dopamine D2 
receptor (DRD2), dopamine D3 receptor (DRD3), dopamine D4 receptor (DRD4), dopamine D5 receptor (DRD5), dystrobrevin 
binding protein 1 (DTNBP1), dyslexia susceptibility 1 candidate 1 (DYX1C1), euchromatic histone-lysine N-methyltransferase 1 
(EHMT1), euchromatic histone-lysine N-methyltransferase 2 (EHMT2), erythropoietin (EPO), erythropoietin receptor (EPOR), v-erb-
b2 avian erythroblastic leukemia viral oncogene homolog 4 (ERBB4), phenylalanyl-tRNA synthetase 2, mitochondrial (FARS2), 
fibroblast growth factor 2 (basic) (FGF2), fibroblast growth factor receptor 1 (FGFR1), FK506 binding protein 5 (FKBP5), gamma-
aminobutyric acid (GABA) A receptor, alpha 6 (GABRA6), glutamate decarboxylase 1 (brain, 67kDa) (GAD1), glycoprotein M6A 
(GPM6A), glutamate receptor, ionotropic, N-methyl-D-aspartate, subunit 2A (GRIN2A), glutamate receptor, ionotropic, N-methyl-D-
aspartate, subunit 2B (GRIN2B), glutamate receptor, metabotropic, 3 (GRM3), glutathione S-transferase-1 (GST-1), glutathione S-
transferase (GST-2), hairy/enhancer-of-split related with YRPW motif 1 (HEY1) , human leukocyte antigen (HLA), serotonin 1A 
receptor (HTR1A), serotonin 2A receptor (HTR2A), LIM domain only 1 (LMO1), leucine rich repeat transmembrane neuronal 1 
(LRRTM1), LSM1 homolog, U6 small nuclear RNA associated (LSM1), MAD1 mitotic arrest deficient-like 1 (MAD1L1), myelin-
associated glycoprotein (MAG), MicroRNA 137 (MIRN137), mitochondrial pyruvate carrier 2 (MPC2), methylenetetrahydrofolate 
reductase (NAD(P)H) (MTHFR), 5-methyltetrahydrofolate-homocysteine methyltransferase (MTR), 5-methyltetrahydrofolate-
homocysteine methyltransferase reductase (MTRR), N-acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase (NAGPA), 
norepinephrine transporter (NET, also known as SLC6A2), nuclear factor of kappa light polypeptide gene enhancer in B-cells 
inhibitor-like 1 (NFKBIL1), nitric oxide synthase 1 (neuronal) (NOS1), neuropeptide Y (NPY), NAD(P)H dehydogenase, quinone 1 
(NQO1), neuregulin 1 (NRG1), neuregulin 3 (NRG3), neurogranin (protein kinase C substrate, RC3) (NRGN), neuritin 1 (NRN1), 5’-
nucleotidase, cytosolic II (NT5C2), oligodendrocyte lineage transcription factor 2 (OLIG2), purinergic receptor P2X, ligand-gated ion 
channel, 7 (P2RX7), prostate-specific transcript (non-protein coding) (PCGEM1), phosphatidylinositol-5-phosphate 4-kinase, type II, 
alpha (PIP4K2A), PBX/knotted 1 homeobox 1 (PKNOX1), phospholipase C, gamma 2 (PLCG2), protein phosphatise 1, regulator 
(inhibitor) subunit 1B (PPP1R1B), PR domain containing 2, with ZNF domain (PRDM2), protein kinase, cAMP-dependent, catalytic, 
gamma (PRKACG), protein kinase C, alpha (PRKCA), protein kinase, cGMP-dependent, type 1 (PRKG1), proline dehydrogenase 
(oxidase) 1 (PRODH), quaking (QKI), Ras-specific guanine nucleotide-releasing factor 2 (RASGRF2), regulator of G-protein 
signalling 2, 24kDa (RGS2), regulator of G-protein signalling 4 (RGS4), roundabout, axon guidance receptor, homolog 1 (Drosophila) 
(ROBO1), sodium channel, voltage-gated, type II, alpha subunit (SCN2A), serologically defined colon cancer antigen 8 (SDCCAG8), 
vesicular monoamine transporter 2 (SLC18A2), zinc finger, spermatogenesis associated 7 (SPATA7), saitohin (STH), synaptosomal-
associated protein 25 (SNAP-25), T-box 1 (TBX1), transcription factor 4 (TCF4), translin-associated factor X (TRAX), SWIM-type 
containing 6 (ZSWIM6).
Abbreviations for tests: American National Adult Reading Test (ANART), Brief Assessment of Cognition in Schizophrenia (BACS), 
Brief Visuospatial Memory Test-Revised (BVMT-R), California Verbal Learning Test (CVLT), Cambridge Automated Test Battery 
(CANTAB), Clinical Dementia Rating Scale (CDR), confidence interval (CI), Controlled Oral Word Association Task (COWAT), 
Continuous Performance Task (CPT), CPT-Degraded Stimulus (CPT-DS), CPT-Identical Pairs (CPT-IP), Delis-Kaplan Executive 
Function System (D-KEFS), Edinburgh Handedness Inventory (EHI), Executive Interview (EXIT), Hopkins Verbal Learning Test-
Revised (HVLT-R), F, A, S letters verbal fluency test (FAS), Intra-Extra Dimensional Set Shifting Task (IED), Inspection Time (IT), 
Letter Number Sequencing (LNS), Operational Criteria Checklist for Psychotic Illness (OPCRIT), NIMH Measurement and Treatment 
Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB), Mini-Mental Status 
Examination (MMSE), Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT), Neuropsychological Assessment Battery 
(NAB), National Adult Reading Test-revised (NART), Neurological Evaluation Scale (NES), Positive and Negative Syndrome Scale 
(PANSS), quality control (QC), Rey Auditory Verbal Learning Test (RAVLT), RAVLT-Delayed Word recall (RAVLT-DW), 
Repeatable Battery for Assessment of Neuropsychological Status (RBANS), Rey Complex Figure Test (RCFT), Theory of Mind 
(ToM), Sustained Attention to Response Task (SART), Social Cognitive Assessment Profile (SCAP), Shipley Institute of Living Scale 
(SILS), standard rehabilitation treatment (SRT), Touchstone Applied Science Associates, Inc. (TASA), Spanish version of the 
California Verbal Learning Test (TAVEC), Trail Making Test (TMT), Verbaler Lern- and Merkfähigkeitstest (VLMT), Weschsler 
Adult Intelligence Scale (WAIS), Wechsler Adult Intelligence Scale-Revised (WAIS-R), Wechsler Abbreviated Scale of Intelligence 
(WASI), Wechsler Memory Scale (WMS), Wechsler Intelligence Scale for Children (WISC), WMS-Revised (WMS-R), Wechsler 
Test of Adult Reading (WTAR), Wisconsin Card Sorting Test (WCST).
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HIGHLIGHTS:
 Schizophrenia patients present with impaired cognitive functions.
 Evidence suggests strong genetic etiology for cognitive deficits in schizophrenia.
 Neurotransmitter system genes showed effect on cognitive deficits in schizophrenia.
 Limited evidence suggests the dopaminergic system genes with inconsistent findings.
 Larger samples are required to examine genetic risk of cognition in schizophrenia.
